language_icon
EN
HI

Alivus Life Sciences Share price

ALIVUS

1060.8

0.80 (-0.08%)
NSE
BSE
Last updated on 20 May, 2026 | 15:31 IST
Today's High

1079.30

Today's Low

1052.10

52 Week Low

819.00

52 Week High

1225.10

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Alivus Life Sciences Chart

Alivus Life Sciences Share Key Metrics

Volume
66607.00
Market Cap
13019.87 CR
LTQ@LTP
1@1060.80
ATP
1063.23
Var Margin
16.55 %
Circuit Range
849.3-1273.9
Delivery %
50.41 %
Value
7.08 CR
ASM/GSM
No
Market Lot
1

Summary

Alivus Life Sciences share price is ₹1060.8 as of 21 May, 2026. The stock Alivus Life Sciences intraday movement has stayed between ₹1052.10 and ₹1079.30, while on a 52-week basis,Alivus Life Sciences price 52 week high is ₹1225.10 & its 52 week low is ₹819.00.
In terms of trading activity, Alivus Life Sciences has recorded a volume of 66607 shares, The Alivus Life Sciences has a market cap of ₹122736348 CR. The stock’s Average Traded Price (ATP) stands at ₹1063.23, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 1 @ ₹1060.80.
Alivus Life Sciences operates within a circuit range of ₹849.30 – ₹1273.90, with a Value of ₹7.08 CR. The Delivery Percentage for the day is 50.41%. Additionally, Alivus Life Sciences currently falls under the No framework, and trades with a market lot size of 1.

Alivus Life Sciences Fundamentals

View More
P/E Ratio

0

P/B Ratio

0

Div. Yield

0

Sector P/E

71.7

Sector P/B

3.51

Sec. Div. Yield

0.56

Alivus Life Sciences Resistance and Support

Pivot 1062.23

Resistance

First Resistance

1074.26

Second Resistance

1086.93

Third Resistance

1098.96

Support

First Support

1049.56

Second Support

1037.53

Third Support

1024.86

Alivus Life Sciences Shareholding Pattern

View More
  • 2022-23
  • 2023-24
  • 2025-26
  • 2026-27
  • 2024-25
  • 2021-22
Total Promoters
Segment
Percent

Total Promoters

82.85%

Mutual Fund

0.32%

Insurance

0%

Foreign Institutional Investors

8.32%

Domestic Institutional Investors

0.15%

Retail

8.36%

Others

0%

Total Promoters
SEP '21
82.84%
DEC '21
82.85%

Alivus Life Sciences Corporate Actions

DateAgenda
2026-05-14Audited Results & Final Dividend
2026-01-22Quarterly Results
2025-11-06Quarterly Results
2025-08-01Quarterly Results
2025-05-15Audited Results & Final Dividend
2025-01-23Quarterly Results

Alivus Life Sciences News

Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Alivus Life Sciences announced upcoming investor meetings on May 25 and 27, 2026. The company will meet with Ambit India Access and Abakkus Asset Managers in Mumbai.
May 20 2026 16:05:00

Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Alivus Life Sciences will conduct a virtual one-on-one analyst/investor meeting with Karma Capital on May 22, 2026. This meeting facilitates direct engagement with institutional investors.
May 19 2026 17:05:00

Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Alivus Life Sciences uploaded the audio recording of its Q4 and FY2026 Earnings Call held on May 15, 2026. This provides investors access to the detailed discussion regarding the company's financial performance.
May 15 2026 14:05:00

Alivus Life Sciences Limited

Alivus Life Sciences' Board has recommended a final dividend of Rs. 5 per equity share. The record date and general meeting date for this dividend are yet to be fixed.
May 14 2026 20:05:00

Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Alivus Life Sciences reported strong FY26 performance with revenue up 6.9% to Rs. 25,518 Mn and EBITDA up 19.6%. The company also announced plans for a new state-of-the-art R&D centre and capacity expansion, signaling future growth.
May 14 2026 20:05:00

Alivus Life Sciences Ltd - 543322 - Board Meeting Intimation for Considering And Approving Audited Financial Results Of The Company For The Quarter And Year Ended 31St March, 2026 And To Consider And Recommend Dividend, If Any, On Equity Shares For The Year Ended March 31, 2026.

Alivus Life Sciences' Board of Directors will hold a meeting on May 14, 2026. The agenda includes considering and approving the audited financial results for the quarter and year ended March 31, 2026, and a potential dividend recommendation.
May 07 2026 19:05:00
Read More

About Alivus Life Sciences

NSE : 5265  
BSE : 543322  
ISIN : INE03Q201024  

The Company was incorporated as ‘Zorg Laboratories Private Limited’ a private limited company under the Companies Act 1956 on June 23 2011 at Pune and was granted the certificate of incorporation by the RoC. the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4 2018. For further details please see – “Details regarding material acquisitions or divestments of business/ undertakings mergers amalgamations or any revaluation of assets in the last 10 years - Acquisition by Glenmark Pharmaceuticals Limited” on page 151. Pursuant to the acquisition the name of the Company was changed to ‘Glenmark Life Sciences Private Limited’ by way of a special resolution passed by the shareholders of the Company on July 25 2018 and a fresh certificate of incorporation dated August 10 2018 was issued by the RoC. A shareholders’ resolution was passed on August 13 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28 2018 was issued by the RoC. Thereafter the business of active pharmaceutical ingredients was acquired by the Company from the Promoter pursuant to the Business Purchase Agreement.Major events and milestones of the Company :2021- Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally2019- The API business was spun off into the Company- Ankleshwar plant inspected by US-FDA Health Canada and PMDA Japan2018- Dahej plant inspected by EDQM ANSM and US-FDA- Mohol plant inspected by US-FDA2016- Dahej plant inspected by PMDA Japan2015- Dahej plant inspected by US-FDA2013- Commenced manufacturing at Dahej Gujarat- Ankleshwar plant inspected by COFEPRIS2012- Ankleshwar plant inspected by PMDA and AFSSAPS2008- Ankleshwar plant at Gujarat inspected by US-FDA2004- Commenced manufacturing at Mohol Maharashtra2003- First product registered with US-FDA- Acquired GlaxoSmithKline’s (GSK) API manufacturing plant in Ankleshwar Gujarat2001 - 2002- The Promoter established its API business- Established manufacturing plant at Kurkumbh MaharashtraAwards accreditations and recognitions received by the Company :2021- Ankleshwar plant received ISO 45001:2018 certifying the management system of the manufacturing facility- Ankleshwar plant received ISO 14001:2015 re-certifying the management system of the manufacturing facility2020- Dahej plant received ISO 45001:2018 certifying the management system of the manufacturing facility- Dahej plant was declared the winner of the Greentech Environment Award for the year 2020 for outstanding achievements in environment protection2019- Ankleshwar plant was awarded Greentech Safety Award as the winner in the pharmaceutical sector by the Greentech Foundation for outstanding achievements in safety management- Dahej plant was awarded Greentech Safety Award for the year 2019 as the runner-up in the pharmaceutical sector by the Greentech Foundation for outstanding achievements in safety management- Dahej plant was declared the winner of the Greentech Environment Award for the year 2019 for outstanding achievements in environment management in the pharmaceutical sector2018- Ankleshwar plant received ISO 14001:2015 re-certifying the management system of manufacturing facility- Dahej plant received ISO 14001:2015 re-certifying the management system of manufacturing facility- Ankleshwar plant was awarded Greentech Safety gold award by the Greentech Foundation for outstanding achievements in safety management2017- Ankleshwar plant was awarded Greentech Safety silver award by the Greentech Foundation for outstanding achievements in safety management2016- Dahej plant received ISO 14001:2015 certifying the management system of manufacturing facility- Ankleshwar plant received BS OHSAS 18001:2017 certifying the management system of the manufacturing facility2015- Ankleshwar plant received ISO 14001:2015 certifying the management system of manufacturing facility

Read More

Alivus Life Sciences Management

NamePosition
Rudalf CorrieaCompany Secretary & Compliance Officer
Hiren K PatelChairman
View More

Alivus Life Sciences FAQs

The Buying Price of Alivus Life Sciences share is 1060.8 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Alivus Life Sciences stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Alivus Life Sciences, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Alivus Life Sciences shares is 0. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Alivus Life Sciences shares is 0. Useful to assess the stock's value relative to its book value.

To assess Alivus Life Sciences’s valuation compare Sector P/E, P/B which are 71.7 & 3.51 with sector averages, along with growth rates and financial metrics.

The Market Cap of Alivus Life Sciences is 13019.87 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Alivus Life Sciences share price is 1225.10 & 819.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Alivus Life Sciences belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost